Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback